John W. Kozarich has demonstrated a clear selling bias in his recent insider transactions, exclusively divesting shares of Ligand Pharmaceuticals (LGND) across multiple filings. Since November 2025, Kozarich executed 25 sales totaling approximately $769,516, with no offsetting purchases during this period. The transactions occurred in concentrated clusters, most notably on March 2, 2026, when he sold six separate blocks of LGND shares ranging from $8,216 to $40,736, and February 2, 2026, when he disposed of four blocks including a single $74,814 transaction. Earlier activity followed a similar pattern, with November 2025 sales including a $39,588 disposition and December 2025 featuring six sales including a $34,861 transaction.
Kozarich’s trading history shows exclusive focus on LGND, with all 37 recorded transactions involving the biopharmaceutical company. The aggregate sell-side activity—$769,516 in proceeds—dwarfs his lifetime buy-side investments of $113,839 in the same security. The consistency of sales across multiple months, often in structured increments, suggests systematic divestment rather than isolated rebalancing. While the filings don’t specify whether these transactions represent option exercises or outright sales, the directional pattern reflects sustained reduction in Kozarich’s LGND position through early 2026.
AI-assisted summary